Lancet Healthy Longevity最新文献

{"title":"Measuring and monitoring the quality of dying in the UN Decade of Healthy Ageing","authors":"Prof Rowan H Harwood MD ,&nbsp;Jotheeswaran Amuthavalli Thiyagarajan PhD ,&nbsp;Afsan Bhadelia PhD ,&nbsp;Andrea Foebel PhD ,&nbsp;Catriona R Mayland MD ,&nbsp;Chetna Malhotra MD ,&nbsp;Prof Deborah Blacker MD ,&nbsp;Prof Elizabeth L Sampson MD ,&nbsp;Prof Eric Andrew Finkelstein PhD ,&nbsp;Harmehr Sekhon PhD ,&nbsp;Prof Jean Woo MD ,&nbsp;Prof Jenny T van der Steen PhD ,&nbsp;Prof Julia Verne PhD ,&nbsp;Prof Leon Geffen MBChB ,&nbsp;Lieve Van den Block PhD ,&nbsp;Mayaline Youssef MSc ,&nbsp;Megan Doherty MD ,&nbsp;Moise Muzigaba PhD ,&nbsp;Muthoni Gichu MB ,&nbsp;Sarah Hopkins MB ,&nbsp;Anshu Banerjee PhD","doi":"10.1016/j.lanhl.2025.100739","DOIUrl":"10.1016/j.lanhl.2025.100739","url":null,"abstract":"<div><div>WHO aims to identify metrics to monitor the quality of dying, complementing those indicators proposed under the UN Decade of Healthy Ageing. However, the proposed criteria for a good death are contentious. Needs and priorities vary between individuals and their carers, across conditions, over time, and across communities and cultures. Monitoring should also consider sudden or rapid deaths and assisted dying. Fundamental challenges in data collection include who reports, over what timeframe, and when. This Personal View explores these challenges, identifying potentially measurable indicators and ambiguities in their use, and offers recommendations towards a practical measurement framework. We aimed to define a concise, meaningful, and pragmatic set of indicators that could be collected and applied universally across countries and over time. We define a logic model of candidate variables at different conceptual levels and describe an empirical exercise for prioritising and operationalising these variables for measurement.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 7","pages":"Article 100739"},"PeriodicalIF":14.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors related to blood-based biomarkers for neurodegenerative diseases and their intergenerational associations in the Young Finns Study: a cohort study","authors":"Marja A Heiskanen PhD ,&nbsp;Juha Mykkänen PhD ,&nbsp;Prof Katja Pahkala PhD ,&nbsp;Markus Juonala MD PhD ,&nbsp;Prof Mika Kähönen MD PhD ,&nbsp;Prof Terho Lehtimäki MD PhD ,&nbsp;Prof Tomi P Laitinen MD PhD ,&nbsp;Prof Eero Jokinen MD PhD ,&nbsp;Päivi Tossavainen MD PhD ,&nbsp;Anna Linko-Parvinen MD PhD ,&nbsp;Hanna-Mari Pallari PhD ,&nbsp;Prof Kaj Blennow MD PhD ,&nbsp;Prof Henrik Zetterberg MD PhD ,&nbsp;Prof Jorma Viikari MD PhD ,&nbsp;Prof Olli Raitakari MD PhD ,&nbsp;Suvi P Rovio PhD","doi":"10.1016/j.lanhl.2025.100717","DOIUrl":"10.1016/j.lanhl.2025.100717","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Blood-based biomarkers (BBM) of neurodegenerative diseases are emerging as cost-effective tools in the differential diagnostics of Alzheimer’s disease and other dementias. Scarce data exist about factors explaining BBM variation in population-based cohorts, and their intergenerational associations are unknown. This study aimed to characterise BBM distributions among a population-based cohort, investigate the association of a wide array of factors with BBM both in midlife and old age, and investigate intergenerational associations of BBM.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We measured BBM detecting amyloid β and tau pathologies, including amyloid β42, amyloid β40, and phosphorylated Tau (pTau)-217, as well as glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) in the multigenerational Young Finns Study participants (n=1237, age 41–56 years) and their parents (n=814, age 59–90 years) using the Quanterix Simoa HD-X analyser. Standard statistical methods were used to examine the associations between BBM and age, sex, genetic factors, a plethora of cardiometabolic markers, liver and kidney function, and lifestyle factors, as well as their intergenerational associations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Increased age was associated with adverse BBM concentrations. Of the various investigated factors, the most robust associations towards adverse BBM concentration were found for &lt;em&gt;APOE&lt;/em&gt; ε4 carrier status among parents (amyloid β42:40 ratio, pTau-217, and GFAP) and high serum creatinine concentration in both generations (pTau-217, GFAP, and NfL). Several factors related to glucose metabolism and dyslipidaemia were negatively associated with all BBM, but adjusting for BMI diluted many of these associations. Statistically significant intergenerational correlations ranged from 0·20 to 0·33 and were mostly observed between mothers and offspring in pTau-217, GFAP, and NfL. No intergenerational correlations existed in amyloid β42:40 ratio.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;We identified several factors that might influence BBM concentrations, parental transmission being one of them. For reliable use of BBM in clinical practice, it is important to identify which factors directly link to amyloid β and tau pathology and which factors influence BBM concentrations due to other physiological processes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;Research Council of Finland, Social Insurance Institution of Finland, Competitive State Research Financing of the Expert Responsibility area of the Kuopio, Tampere and Turku University Hospitals, Juho Vainio Foundation, Paavo Nurmi Foundation, Finnish Foundation for Cardiovascular Research, Finnish Cultural Foundation, The Sigrid Juselius Foundation, Tampere Tuberculosis Foundation, Emil Aaltonen Foundation, Yrjö Jahnsson Foundation, Signe and Ane Gyllenberg Foundation, Jenny and Antti Wihuri Foundation, Diabetes Research Foundation of the Finnish Diabetes As","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100717"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144587667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of age on the association of vascular risk factors with acute stroke (INTERSTROKE): a case–control study","authors":"Catriona Reddin MB BCh BAO ,&nbsp;Graeme J Hankey MD ,&nbsp;John Ferguson PhD ,&nbsp;Peter Langhorne PhD ,&nbsp;Shahram Oveisgharan MD ,&nbsp;Michelle Canavan PhD ,&nbsp;Helle K Iversen MD ,&nbsp;Annika Rosengren PhD ,&nbsp;Danuta Ryglewicz PhD ,&nbsp;Anna Czlonkowska PhD ,&nbsp;Xingyu Wang MD ,&nbsp;Fernando Lanas MD ,&nbsp;Albertino Damasceno MD ,&nbsp;Denis Xavier MD ,&nbsp;Patricio Lopez-Jaramillo PhD ,&nbsp;Andrew Smyth PhD ,&nbsp;Salim Yusuf DPhil ,&nbsp;Martin O’Donnell PhD ,&nbsp;INTERSTROKE investigators","doi":"10.1016/j.lanhl.2025.100709","DOIUrl":"10.1016/j.lanhl.2025.100709","url":null,"abstract":"<div><h3>Background</h3><div>The absolute burden of stroke is increasing due to an ageing population, as well as an increased incidence of stroke in young adults. We aimed to determine whether age modifies the magnitude of association between vascular risk factors and stroke in the INTERSTROKE study.</div></div><div><h3>Methods</h3><div>INTERSTROKE is an international case–control study of risk factors for first acute stroke. Cases and controls (matched by age and sex) were recruited in 32 countries (between Jan 11, 2007, and Aug 8, 2015). Participants completed a clinical assessment and provided blood and urine samples within 72 h of recruitment. Odds ratios (ORs) for vascular risk factors and their population attributable fractions (PAFs) were calculated among age groups. We tested for an interaction of age by each risk factor.</div></div><div><h3>Findings</h3><div>Among 26 950 participants, the mean age of cases was 62·2 years (SD 13·6) and of controls 61·3 years (13·3). Increasing age was associated with a significant increased prevalence for seven vascular risk factors (hypertension, physical inactivity, diabetes, atrial fibrillation, high waist-to-hip ratio, high apolipoprotein B concentration [p&lt;0·0001 for all], and obesity [p=0·016]), reduced prevalence for four vascular risk factors (smoking, alcohol use, psychosocial stress [p&lt;0·0001 for all], and unhealthy diet [p=0·0081]) and unchanged prevalence for one vascular risk factor (depression). Increasing age was associated with a reduced magnitude of OR of stroke for hypertension (p_interaction&lt;0·0001), high apolipoprotein B concentration (p_interaction&lt;0·001), high waist-to-hip ratio (p_interaction 0·011), alcohol use (p_interaction&lt;0·0001), and psychosocial stress (p_interaction=0·033). No vascular risk factor was associated with a higher odds of stroke with increased age. Hypertension, high waist-to-hip ratio, and physical inactivity accounted for the largest PAF among all age groups.</div></div><div><h3>Interpretation</h3><div>Vascular risk factors exhibit different patterns of association with stroke by age, with consequent variations in their relative PAF. This information could be used to prioritise risk factor screening and modification by age group.</div></div><div><h3>Funding</h3><div>Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada; Canadian Stroke Network; AFA Insurance, Health Research Board Ireland; Swedish Research Council; Swedish Heart and Lung Foundation; The Health &amp; Medical Care Committee of the Regional Executive Board, Region Västra Götaland (Sweden); AstraZeneca; Boehringer Ingelheim (Canada); Pfizer (Canada); MSD; Chest, Heart, and Stroke Scotland; and The UK Stroke Association.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100709"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gynaecological health of women in nursing homes","authors":"Gaëlle Berhault-Delinde ,&nbsp;Moustapha Drame ,&nbsp;Maturin Tabue-Teguo","doi":"10.1016/j.lanhl.2025.100721","DOIUrl":"10.1016/j.lanhl.2025.100721","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100721"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult social care: insufficient funding and financial pressures","authors":"The Lancet Healthy Longevity","doi":"10.1016/j.lanhl.2025.100737","DOIUrl":"10.1016/j.lanhl.2025.100737","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100737"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-traumatic stress disorder in older adults: a global collaboration on setting the future research agenda","authors":"Sjacko Sobczak PhD ,&nbsp;Vasiliki Orgeta PhD ,&nbsp;Margreet Beenakker MSc ,&nbsp;Marco Boks PhD ,&nbsp;Margherita Boltri PhD ,&nbsp;Monica Cations PhD ,&nbsp;Estelle Coeur MSc ,&nbsp;Joan M Cook PhD ,&nbsp;Xavier Corveleyn PhD ,&nbsp;Ashley-Nicole Dorame BA ,&nbsp;Gea C van Dijk PhD ,&nbsp;Barbara Forresi PhD ,&nbsp;Stéfanie Fréel MSc ,&nbsp;Denise Gómez-Bautista MSc ,&nbsp;Mia Maria Günak MSc ,&nbsp;Demi C D Havermans MSc ,&nbsp;Malcolm Hopwood Prof ,&nbsp;Jiaqing O Prof ,&nbsp;Karen A Lawrence PhD ,&nbsp;Lewina O Lee PhD ,&nbsp;Miranda Olff Prof","doi":"10.1016/j.lanhl.2025.100720","DOIUrl":"10.1016/j.lanhl.2025.100720","url":null,"abstract":"<div><div>Post-traumatic stress disorder (PTSD) in later life poses a substantial burden on public health and social care systems. However, research in this population remains scarce. In this Personal View, we review the current state of research on PTSD and ageing, as presented by the On Traumatic Stress and Ageing: A Global Network task force, part of the Global Collaboration on Traumatic Stress. Evidence-based knowledge on PTSD in older (aged 60 years or older) trauma survivors was synthesised across four clinical domains: ageing mechanisms, assessment, treatment, and care. 142 publications were reviewed to integrate available evidence and establish consensus-based research priorities. The findings highlight the urgent need for high-quality research across all four domains on older trauma survivors. Future studies should focus on older under-represented groups, such as women; individuals with multiple comorbidities, including neurocognitive disorders; and populations in low-income and middle-income countries. Using standard diagnostic instruments, establishing clinically meaningful functional outcomes, and engagement of people with lived experience should be prioritised to be applied in future research.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100720"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital biomarkers of ageing for monitoring physiological systems in community-dwelling adults","authors":"Jessica K Lu MEng ,&nbsp;Weilan Wang PhD ,&nbsp;Muhammad Daniel Azlan Mahadzir PhD ,&nbsp;Jesse R Poganik PhD ,&nbsp;Mahdi Moqri PhD ,&nbsp;Chiara Herzog PhD ,&nbsp;Eric Verdin MD ,&nbsp;Vittorio Sebastiano PhD ,&nbsp;Prof Vadim N Gladyshev PhD ,&nbsp;Andrea B Maier MD","doi":"10.1016/j.lanhl.2025.100725","DOIUrl":"10.1016/j.lanhl.2025.100725","url":null,"abstract":"<div><div>Digital health technologies are transforming health care and personal health management by providing quantifiable data on physiological, behavioural, and environmental health parameters using digital biomarkers. This narrative review classified, characterised, and evaluated digital biomarkers of ageing across ten physiological systems to explore the applications of these biomarkers in research and clinical practice. The systematic search identified minimally invasive or non-invasively measured digital biomarkers suitable for longitudinal studies and practical use by community-dwelling adults. The digital biomarkers were classified according to their physiological system, characterised by their capture methods, and evaluated based on the following criteria: validity (age-associated, function-associated, and mortality-associated), generalisability, responsiveness to interventions, associations with clinical outcomes, and cost-effectiveness in large-scale settings. Digital biomarkers of ageing were found across eight physiological systems. Registered clinical trials that used these digital biomarkers as outcomes were also identified. Continued research and technological advancements are crucial for maximising the potential of digital biomarkers in promoting healthy ageing and longevity.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100725"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Older adults as health volunteers in Nepal for individual and community wellbeing","authors":"Urza Bhattarai ,&nbsp;Sanjib Kumar Sharma","doi":"10.1016/j.lanhl.2025.100722","DOIUrl":"10.1016/j.lanhl.2025.100722","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100722"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is pneumococcal vaccination required for new residents of care facilities for older adults?","authors":"Claire von Mollendorf","doi":"10.1016/j.lanhl.2025.100736","DOIUrl":"10.1016/j.lanhl.2025.100736","url":null,"abstract":"","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100736"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pneumococcal vaccination for new residents entering older adult care homes in England: national observational surveillance study","authors":"Fariyo Abdullahi MSc ,&nbsp;Tara Patel MSc ,&nbsp;Kelly Stoker MSc ,&nbsp;Catherine Carey PhD ,&nbsp;Nick Andrews PhD ,&nbsp;Prof Mary Ramsay FFPH ,&nbsp;Prof Jackie Cassell FRCP ,&nbsp;Shamez N Ladhani PhD","doi":"10.1016/j.lanhl.2025.100726","DOIUrl":"10.1016/j.lanhl.2025.100726","url":null,"abstract":"<div><h3>Background</h3><div>The incidence of invasive pneumococcal disease (IPD) increases rapidly with age. In the UK, adults aged 65 years are eligible for the 23-valent pneumococcal polysaccharide vaccine (PPV23) as part of the national immunisation programme, and a 20-valent pneumococcal conjugate vaccine (PCV20) was recently licensed for adults. Residents of care homes for older adults have a higher risk of IPD and death than the general population. We estimated the potential effect of an additional dose of PPV23 or PCV20 for new residents entering older adult care homes.</div></div><div><h3>Methods</h3><div>In this observational surveillance study, we used national IPD surveillance and care home resident data from England. Care homes for older adults were defined as residential care and nursing homes registered with the Care Quality Commission for adults aged 65 years and older. IPD in adults aged 65 years and older in England was assessed in the 2022–23 epidemiological year (July 1, 2022, to June 30, 2023) by sex and 5-year age bands using data obtained from UK Health Security Agency national IPD surveillance. We calculated the number needed to vaccinate (NNV) with PPV23 or PCV20 in the population of new care home residents to prevent one vaccine-type IPD case and one death compared with adults aged 65 years who were vaccinated as part of the national immunisation programme in England.</div></div><div><h3>Findings</h3><div>In 2022–23, there were 2574 IPD cases among 10 629 867 people aged 65 years and older in England. Of these, 603 109 were aged 65 years. Of the 2574 cases, 69·4% (1787 of 2574) were due to PPV23 serotypes and 60·8% (1566 of 2574) were due to PCV20 serotypes. Under the assumption of 36% vaccine effectiveness against PPV23-type IPD and 18% vaccine effectiveness against death, PPV23, when offered to all 603 109 adults aged 65 years in the general population, could prevent 163 (36%) of 452 cases (NNV 3700) and 31 (47%) of 66 PPV23-type IPD associated deaths over 5 years (NNV 19 455). However, vaccinating 121 587 new care home residents with PPV23 could prevent 177 (36%) of 492 lifetime cases (NNV 687) and 111 (48%) of 233 deaths (NNV 1095). In all adults aged 65 years in the general population, PCV20 could prevent 303 (75%) of 404 cases (NNV 1990) and 43 (80%) of 54 PCV20-type IPD deaths (NNV 14 026), assuming 75% vaccine effectiveness against PCV20-type IPD and 18% against death. However, vaccinating 121 587 new care home residents with PCV20 could prevent 317 (75%) of 422 cases (NNV 384) and 157 (80%) of 197 deaths (NNV 774).</div></div><div><h3>Interpretation</h3><div>Pneumococcal vaccination for new care home residents could prevent substantially more cases and deaths per dose and would require only 20% more doses than the current national PPV23 programme for adults aged 65 years. PCV20 is likely to have a greater impact against IPD and death than PPV23.</div></div><div><h3>Funding</h3><div>None.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 6","pages":"Article 100726"},"PeriodicalIF":13.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}